Endothelin antagonism in pulmonary hypertension, heart failure, and beyond.
作者信息
Attinà T, Camidge R, Newby D E, Webb D J
机构信息
Clinical Research Centre, Department of Medical Sciences, University of Edinburgh, Edinburgh, UK.
出版信息
Heart. 2005 Jun;91(6):825-31. doi: 10.1136/hrt.2004.053991.
Abstract
摘要
相似文献
1
Endothelin antagonism in pulmonary hypertension, heart failure, and beyond.
Heart. 2005 Jun;91(6):825-31. doi: 10.1136/hrt.2004.053991.
2
[Prospects for endothelin-related drugs].
Nihon Rinsho. 2004 Sep;62 Suppl 9:673-81.
3
Role of endothelin-1 in myocardial failure.
Proc Assoc Am Physicians. 1999 Sep-Oct;111(5):417-22. doi: 10.1111/paa.1999.111.5.417.
4
Of mice and men: advances in endothelin research and first antagonist gains FDA approval.
Trends Pharmacol Sci. 2002 Apr;23(4):155-7. doi: 10.1016/s0165-6147(00)01975-1.
5
Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors.
Circulation. 1996 Nov 1;94(9):2131-7. doi: 10.1161/01.cir.94.9.2131.
6
Reversing congestive heart failure with endothelin receptor antagonists.
Circulation. 1997 Apr 1;95(7):1752-4. doi: 10.1161/01.cir.95.7.1752.
7
[Endothelin and kidney disease].
Nihon Rinsho. 2004 Sep;62 Suppl 9:655-60.
8
Endothelin in heart failure: a promising therapeutic target?
Heart. 1997 Feb;77(2):93-4. doi: 10.1136/hrt.77.2.93.
9
Endothelin.
Cell Mol Life Sci. 2011 Jan;68(2):195-203. doi: 10.1007/s00018-010-0518-0. Epub 2010 Sep 17.
10
Endothelin blockers and renal protection: a new strategy to prevent end-organ damage in cardiovascular disease?
Cardiovasc Res. 1998 Sep;39(3):543-9. doi: 10.1016/s0008-6363(98)00155-2.
引用本文的文献
1
The (pro)renin receptor as a pharmacological target in cardiorenal diseaes.
Hypertens Res. 2023 Nov;46(11):2527-2534. doi: 10.1038/s41440-023-01424-6. Epub 2023 Sep 4.
2
Could Endothelin-1 Be a Promising Neurohormonal Biomarker in Acute Heart Failure?
Diagnostics (Basel). 2023 Jul 5;13(13):2277. doi: 10.3390/diagnostics13132277.
3
Aprocitentan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant Hypertension.
Cardiol Ther. 2021 Dec;10(2):397-406. doi: 10.1007/s40119-021-00233-7. Epub 2021 Jul 12.
4
AMPK and Pulmonary Hypertension: Crossroads Between Vasoconstriction and Vascular Remodeling.
Front Cell Dev Biol. 2021 Jun 8;9:691585. doi: 10.3389/fcell.2021.691585. eCollection 2021.
5
Endothelial cells in the pathogenesis of pulmonary arterial hypertension.
Eur Respir J. 2021 Sep 2;58(3). doi: 10.1183/13993003.03957-2020. Print 2021 Sep.
6
The Biological Bases of Group 2 Pulmonary Hypertension.
Int J Mol Sci. 2019 Nov 23;20(23):5884. doi: 10.3390/ijms20235884.
7
Drug Treatment of Hypertension: Focus on Vascular Health.
Drugs. 2016 Oct;76(16):1529-1550. doi: 10.1007/s40265-016-0642-8.
8
MicroRNA and Heart Failure.
Int J Mol Sci. 2016 Apr 6;17(4):502. doi: 10.3390/ijms17040502.
9
Pulmonary Hypertension and Cardiopulmonary Exercise in Heart Failure.
Pulse (Basel). 2014 May;1(3-4):143-51. doi: 10.1159/000360964.
10
Air Pollution-Induced Vascular Dysfunction: Potential Role of Endothelin-1 (ET-1) System.
Cardiovasc Toxicol. 2016 Jul;16(3):260-75. doi: 10.1007/s12012-015-9334-y.
本文引用的文献
1
Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade.
Circulation. 2004 Mar 9;109(9):1186-93. doi: 10.1161/01.CIR.0000118499.69469.51. Epub 2004 Feb 23.
2
Combined endothelin receptor blockade evokes enhanced vasodilatation in patients with atherosclerosis.
Arterioscler Thromb Vasc Biol. 2002 Apr 1;22(4):674-9. doi: 10.1161/01.atv.0000012804.63152.60.
3
Bosentan therapy for pulmonary arterial hypertension.
N Engl J Med. 2002 Mar 21;346(12):896-903. doi: 10.1056/NEJMoa012212.
4
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.
Lancet. 2001 Oct 6;358(9288):1119-23. doi: 10.1016/S0140-6736(01)06250-X.
5
Endothelin system: the double-edged sword in health and disease.
Annu Rev Pharmacol Toxicol. 2001;41:851-76. doi: 10.1146/annurev.pharmtox.41.1.851.
6
Endothelin-converting enzyme inhibitors: current status and perspectives.
J Cardiovasc Pharmacol. 2000;35(4 Suppl 2):S79-82. doi: 10.1097/00005344-200000002-00018.
7
Salt-sensitive hypertension in endothelin-B receptor-deficient rats.
J Clin Invest. 2000 Apr;105(7):925-33. doi: 10.1172/JCI8609.
8
Vasoconstriction to endogenous endothelin-1 is increased in the peripheral circulation of patients with essential hypertension.
Circulation. 1999 Oct 19;100(16):1680-3. doi: 10.1161/01.cir.100.16.1680.
9
Endothelin antagonists.
Lancet. 1999 Jan 9;353(9147):133-8. doi: 10.1016/S0140-6736(98)09423-9.
10
Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men.
Hypertension. 1999 Jan;33(1 Pt 2):581-5. doi: 10.1161/01.hyp.33.1.581.
Zotero 插件